AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Signed informed content obtained prior to treatment * Age ≥18 years and ≤ 80 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤1 * Radiographically confirmed after borderline resectable or locally advanced pancreatic adenocarcinoma. * No any other anti-tumor therapy prior to neoadjuvant chemotherapy, including intervention chemoembolization, ablation, radiotherapy, chemotherapy and molecular targeted therapy. * No any other anti-tumor therapy prior to neoadjuvant chemotherapy, including intervention chemoembolization, ablation, radiotherapy, chemotherapy and molecular targeted therapy. * No serious blood system, heart, lung function abnormalities and immune defects (refer to the respective standards) * White blood cell (WBC) ≥ 3 × 109/L; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelets (PLT) ≥ 100 × 109/L; Hemoglobin (Hgb)≥ 9 g/dL * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) ≤ 2.5 × institutional upper limit of normal (ULN); Total bilirubin (TBIL) ≤ ULN; Creatinine (CRE) ≤ 1.5 × ULN * Prothrombin time (PT) and international normalized ratio (INR) ≤ 1.5 ×ULN * Comply with research visit plans and other program requirements. Exclusion Criteria: * with other systemic malignancies * Patients who were treated with any other anti-tumor therapy prior to neoadjuvant chemotherapy, including intervention chemoembolization, ablation, radiotherapy, chemotherapy and molecular targeted therapy. * used any other study drug within 7 days prior to enrollment; * Patients with central nervous system diseases, mental illness, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases that cannot be controlled * History of allergic reactions attributed to compounds of similar chemical or biological composition to study drug and alike. * Patients who are using and expected to use warfarin in long term * Patients may leave the observation for 14 days or more during the study.